Glucose and Blood Pressure During Pregnancy
Predictive Role of Non-Invasive Glucose Assessment During Pregnancy: A Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Madeline S Reid
- Phone Number: 507-255-0007
- Email: reid.madeline@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55901
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Study Population
Description
Inclusion Criteria:
- Age range: 18-45 years (inclusive)
- Body mass index (BMI) ≤40kg/m2
- >1 risk factor for GDM
- <16wks gestation
- Gender: only females will be recruited into this study
- Ability to provide written informed consent
Exclusion Criteria:
- Presence of chronic kidney disease (creatinine >2.5mg/dL) and/or active cancer
- Smoking
- Multiple pregnancies
- Congenital abnormalities
- Use of chronic medications which influence blood [glucose] or [insulin]
- Subsequent diagnosis of GDM or preeclampsia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Standard of care
|
|
|
Experimental: LabClasp+Standard of care
|
Subjects will complete up to 10 measurements per day with potentially more before and during their OGTT using the LabClasp
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood Glucose
Time Frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 30
|
Blood Glucose will be measured in Mmol/L
|
Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 30
|
|
Systolic Blood Pressure
Time Frame: Baseline
|
Systolic Blood Pressure will be measured in mmHg
|
Baseline
|
|
Diastolic Blood Pressure
Time Frame: Baseline
|
Diastolic Blood Pressure will be measured in mmHg
|
Baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pittsburgh sleep study quality index
Time Frame: Baseline
|
The Pittsburgh Sleep Quality Index measures the severity of sleep disturbances.
Possible scores range from 0 to 21 with higher scores indicating a worse outcome/more severe symptoms of sleep disturbance.
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Virend Somers, MD, PhD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 21-000284
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.